Archive for the ‘research’ Category

Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials

Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…

Our new “Psoriasis Journey” campaign is rolling out
Our new “Psoriasis Journey” campaign is rolling out

Our new Psoriasis Journey campaign is rolling out now to prep for for an official June 8, 2020 launch. On that date, our volunteer patient with severe psoriasis is going to begin one of the cutting-edge psoriasis treatments we’ve been hearing so much about. You can follow along with his Continue Reading…

Want to try an experimental psoriasis treatment for your skin or scalp?
Want to try an experimental psoriasis treatment for your skin or scalp?

Before a doctor can prescribe a treatment, it goes through years of research and testing, including multiple rounds of clinical trials, using volunteer patients to test a potential treatment’s safety and effectiveness. The clinical trials are developed in consultation with government regulators (here, the US Food and Drug Administration, or Continue Reading…

Cosentyx goes head to head against Humira in psoriatic arthritis…it’s mostly a draw
Cosentyx goes head to head against Humira in psoriatic arthritis…it’s mostly a draw

Two biologics that work on psoriatic disease differently – Cosentyx (drug name secukinumab, an IL-17a inhibitor) and Humira (drug name adalimumab, a TNF-alpha inhibitor) – were recently tested in a study designed and funded by Novartis, the company behind Cosentyx. The study pitted Cosentyx against Humira for 52 weeks in Continue Reading…

New patient registry PsoProtect for those battling both psoriasis and COVID-19/coronavirus could help provide treatment insights to both ailments
New patient registry PsoProtect for those battling both psoriasis and COVID-19/coronavirus could help provide treatment insights to both ailments

Scientists and physicians in the UK, working with an international coalition of experts and organizations, have launched a web-based registry that will gather health information on people with psoriasis who develop confirmed or suspected COVID-19/coronavirus. The results, if enough doctors participate, could provide important information in the treatment of both Continue Reading…

Do I need to worry about links between psoriasis and Alzheimer’s disease?
Do I need to worry about links between psoriasis and Alzheimer’s disease?

You may have seen the headlines: “Psoriasis tied to higher Alzheimer’s disease risk.” Great. Just another thing to worry about thanks to psoriasis, right? But when you dig into the research, you realize it’s mostly just the usual media hype: there’s no need to panic the next time you misplace Continue Reading…

Amgen to test Otezla as possible COVID-19 coronavirus treatment
Amgen to test Otezla as possible COVID-19 coronavirus treatment

Biotech giant Amgen, known in the psoriasis world for its longtime blockbuster Enbrel (etanercept), a biologic used in the treatment of psoriasis and psoriatic arthritis, has announced that the company “plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.” Continue Reading…

Reading this article about the placebo effect will make you feel better today

Here’s a very interesting item about the placebo effect. Yes, it is fun to hear about experiments in which people can be fooled into feeling better, or worse. But more importantly, this professor and psychologist discusses how a patient’s attitude, and a physician’s warmth and (apparent) competence, can impact our Continue Reading…

Imagine knowing after 4 weeks, how a new psoriasis treatment would be working for you after 6 months…

Here’s an interesting, after-the-fact analysis from clinical trials of the biologic Ilumya (tildrakizumab-asmn), an “IL-23 inhibitor” marketed by Sun Pharma. The researchers looked at psoriasis severity scores used in clinical trials, known as PASI scores (Psoriasis Area and Severity Index), for each patient. Each patient’s score is determined before the Continue Reading…

Opioid use “substantial” among people with moderate to severe psoriasis

A recent study looked at a database of privately insured people that included about 9,000 psoriasis patients, of whom just over 2,000 were identified as having moderate to severe psoriasis. It found that about 25% of those 2,000 received opioids, compared to 16% of otherwise-comparable people without psoriasis. The figure Continue Reading…